Company Filing History:
Years Active: 2023-2024
Title: Ville Pietila: Innovator in Radiation Therapy
Introduction
Ville Pietila is a prominent inventor based in Helsinki, Finland. He has made significant contributions to the field of radiation therapy through his innovative patents. With a total of 5 patents, his work focuses on enhancing treatment planning and dose distribution analysis using advanced technologies.
Latest Patents
One of his latest patents is titled "Machine learning-based generation of 3D dose distributions for volumes not included in a training corpus." This invention involves a machine learning model that predicts three-dimensional dose distributions for patient volumes not represented in the training data. The model utilizes information about the patient to generate accurate predictions for treatment plans.
Another notable patent is "Artificial intelligence modeling for radiation therapy dose distribution analysis." This patent describes methods and systems that optimize radiation therapy treatment plans using dose distribution values predicted by a trained AI model. The server trains the AI model with data from previous treatments and predicts dose distributions for new patients, ultimately aiding in the creation of optimized treatment plans.
Career Highlights
Ville Pietila has worked with leading companies in the medical technology sector, including Siemens Healthineers and Varian Medical Systems. His experience in these organizations has allowed him to develop and refine his innovative ideas in radiation therapy.
Collaborations
Throughout his career, Ville has collaborated with notable professionals in the field, including Jarkko Yriana Peltola and Marko Rusanen. These collaborations have contributed to the advancement of his research and the successful implementation of his inventions.
Conclusion
Ville Pietila's contributions to radiation therapy through his innovative patents demonstrate his commitment to improving patient care. His work in machine learning and artificial intelligence continues to shape the future of treatment planning and dose distribution analysis.